Outcome of Targeted Therapy Recommendations for Metastatic and Recurrent Head and Neck Cancers.

ABSTRACT: Recurrent/metastatic (R/M) head and neck cancers bear a poor prognosis. In this analysis, we examined the efficacy and the outcome of targeted therapy recommendations based on the patients' molecular tumor portrait after failure of all standard therapy options. In this single-center, real-world retrospective analysis of our platform for precision medicine, we analyzed the molecular profile of 50 patients diagnosed with R/M head and neck cancer. Tumor samples of the patients were examined using next-generation sequencing panels of mutation hotspots, microsatellite instability (MSI) testing, and immunohistochemistry (IHC). In 31 cases (62.0% of all patients), a molecular-driven targeted therapy approach was recommended. Eventually, 14 patients (28%) received the suggested targeted therapy. S

SUBMITTER: Taghizadeh H 

PROVIDER: S-EPMC7696688 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature